Presentation is loading. Please wait.

Presentation is loading. Please wait.

May 2008 Company Presentation UK. - Confidential - 2 FlowMedic’s goal is to be a global market leader providers of innovative, non-invasive medical devices.

Similar presentations


Presentation on theme: "May 2008 Company Presentation UK. - Confidential - 2 FlowMedic’s goal is to be a global market leader providers of innovative, non-invasive medical devices."— Presentation transcript:

1 May 2008 Company Presentation UK

2 - Confidential - 2 FlowMedic’s goal is to be a global market leader providers of innovative, non-invasive medical devices for prevention and treatment of venous and arterial circulatory disorders in the extremities for both the medical and the OTC consumer markets Mission Statement

3 - Confidential - 3 Flowmedic Structure Established in 2003 Privately owned by IBV private equity investment group Fully owned subsidiaries in Israel (R&D) and the US (sales & marketing) Outsourced manufacturing firmly established in China

4 - Confidential - 4 Core Technology and Applications Core Technology Professional / Hospital Home / Managed Care Outpatient Clinics OTC / Consumer Post Op DVT Prophylaxis Pre Op DVT Prophylaxis Venus Ulcer Healing DVT Treatment PAD Intermittent Claudication Neuropathy DVT Prophylaxis Improved Circulation Edema reduction Blood Stimulation DVT Prophylaxis PAD CLI Neuropathy Wound Healing

5 - Confidential - 5 FlowMedic Scope of Products & Indications Venous Indications DVT Prophylaxis (ortho, trauma, bariatric, stroke) DVT Treatment Arterial Indications Peripheral Arterial Disease (PAD) Intermittent Claudication (IC) Critical Limb Ischemia (CLI) Diabetic Indications Extremities Ulcers Wound Healing (WH) Neuropathy (N) Health & Wellness (OTC) DVT Prevention Blood Stimulation Edema Reduction  Actual  Future Peripheral Arterial Disease

6 - Confidential - 6 Market Opportunity FlowMedic products are geared towards a population of million European and double that number worldwide affected by crippling and costly venous/ arterial and correlated disease indications, representing cumulative addressable markets of over $3.0 billion in revenues

7 - Confidential - 7 Arterial Disease Implications Peripheral Arterial Disease (PAD) affects 12 million U.S. citizens and approximately 30 million people worldwide (F&S and Datamonitor 2004) Approximately 20% of the population over 70 and 30% of all diabetics are thought to have PAD (Clinical Cardiology Review, 2002) Close to one million Americans are diagnosed for leg pain caused by poor vascular circulation, called Intermittent Claudication (ADA Consensus Statement) Critical Limb Ischemia (CLI), a PAD related condition, affects 750,000 individuals in the United States, primarily diabetics Every year, over 150,000 lower limb amputations are performed in the U.S. due to severe PAD and CLI Leg ulcers affect as many as 2.5 million people in the U.S. causing substantial pain and loss of function Severity StageSeverity Stage

8 PAD Prevalence Data Higher Prevalence and Mortality than Many Leading Diseases

9 - Confidential - 9 Flowmedic Unique Elastic Recoil™ Physiological Effect Improved circulation in arteries that may be stiff due to diabetes, atherosclerosis, or other circulatory problems without causing user discomfort and associated low compliance– a major drawback of Intermittent Pneumatic Compression (IPC) devices Increases arterial-venous pressure differences (by enhancing venous return) through mechanical compression Improves pain-free walking distance Improve quality of life

10 - Confidential - 10 FM220 TM Arterial Circulation System Features Portable Easily operated by patients Data logger for patient follow-up Light weight Battery operated Improved hemodynamic performance at lower lower peak pressure Status FDA 510K clearance and CE certified HCPCS code attained for arterial compression therapy Completed clinical trials in PAD and Claudicant subjects Ongoing multi center clinical trial in US Commercially launched in the EU Cleared by the FDA & CE mark Improved Patient Compliance

11 - Confidential - 11 The OTC opportunity - Some Statistic Numbers…. SOURCE: Reuters Business Insight; Internet sources, National Heart, Lung and Blood Institute; Scurr JH,(2001) Lancet, 357, 1485–1489; Jacobson BF, S Afr Med J Jul;93(7):522-8; Hughes RJ,Lancet Dec 20;362(9401): Over 250 million people with high income aged living in Western countries More than 500 million people fly > 4 hours flights annually Clinical studies show that 1- 10% of fliers develop DVT In the US, there are more than 18,750 air travel related DVT cases per month 30,000 world wide estimated flight related DVT deaths cases every year

12 - Confidential - 12 Product Description Aviafit TM /Homefit TM is a light-weight, portable product that apply mechanical compression to stimulate circulation of blood in the legs while creating a pleasant, massage effect Aviafit TM /Homefit TM prevents blood stagnation, and reduces the risk of life-endangering blood cloth formation

13 - Confidential - 13 Aviafit TM /Homefit TM Pulsating Leg Band Features Convenient: very small footprint & lightweight Worn on both legs, over or under the clothing Portable, for use at home, office or travel Simple to use Pleasant massage effect 20 hours of continuous battery operation Status Completion of in vitro verification, validation data and clinical data showing the positive effect of the product on flow parameters CE Mark received FDA clearance under 510K Class II classification Successful launched in Europe through pharmacy channels (> 1,000 PO’s) Reusable Strap Device Body Device Panel

14 - Confidential - 14 Aviafit TM /Homefit TM Benefits Improve wellbeing and quality of life Effectively stimulates blood circulation in the legs, reducing the risk of Deep Vein Thrombosis (DVT) Effective results even while user is passive Portable, battery-operated permits movement during use Pleasant massage-like feeling Applicable over or under the clothing – whatever is more convenient Excellent alternative to elastic socks, medicine and foot massagers

15 - Confidential - 15 Intellectual Property 54 filed and 19 granted / published patent applications PCT- WO 02/ – A portable device for the enhancement of circulation and for the prevention of stasis related deep vein thrombosis. Priority date: 5 March 2001 ( Published 12 Sep 2002) 24 new patent applications filed since (including also CIP applications and PCT applications) National phase filed in USA, Japan, Canada, China, India, Australia, New Zealand, Brazil, Mexico, a regional phase in Europe and registration in Hong Kong 5 registered trademarks 3 in Europe (CTM) and 2 in Japan 11 trademark applications: 3 in Europe (CTM), 6 in the U.S. and 2 in Israel

16 - Confidential - 16 Company Management and Medical Advisory Board Company Management Prof. Shlomo Ben-Haim, MD - Co-Founder and Chairman Lewis C. Pell – Co-Founder and Director Dr. Benny Rousso - Co-Founder, Director and CTO Nissim Greisas – General Manager Medical Advisory Board Prof. Daniel Burkhoff – Leading researcher in the cardiovascular field. Adjunct Associate Professor at Columbia University John Scurr, MD – Middlesex Hospital and University College Hospital, London Ron Karmeli, MD - Chief of the Vascular Surgery Department, Carmel Hospital, Haifa, Israel Benjamin Brenner, MD - Director of the Thrombosis and Homeostasis Unit and Deputy Director of the Department of Hematology at the Rambam Medical Center in Haifa, Israel


Download ppt "May 2008 Company Presentation UK. - Confidential - 2 FlowMedic’s goal is to be a global market leader providers of innovative, non-invasive medical devices."

Similar presentations


Ads by Google